Did HCA's earnings growth come from core operations or one-time items?

Mostly core operations. Q1 2024 included a $201 million pre-tax gain on facility sales ($154 million after tax, or $0.57 per diluted share), while Q1 2025 had only a negligible $1 million gain. Excluding these items, adjusted EPS rose from $5.36 to $6.45, about 20%, and Adjusted EBITDA grew 11.3%. Part of the EPS growth also reflects a lower share count, which fell from 268.0 million to 249.4 million diluted shares following buybacks.

Why did operating cash flow decline so much, and should investors be concerned?

Operating cash flow dropped to $1.651 billion from $2.469 billion, mainly because of a $1.000 billion decrease from accounts payable and accrued expenses and a $327 million increase in accounts receivable. Accounts receivable rose to $11.088 billion. Working capital timing can reverse in later quarters, but investors should monitor whether collections and payables normalize. Operating cash flow of $1.651 billion still exceeded capital expenditures of $991 million, and HCA's buybacks of $2.506 billion were funded in part by new debt issuance of $5.233 billion.

Is HCA's guidance changing for 2025?

No. The company reaffirmed the 2025 ranges issued in January 2025: revenue of $72.8–$75.8 billion, Adjusted EBITDA of $14.3–$15.1 billion, and diluted EPS of $24.05–$25.85 on 243 million diluted shares. Guidance assumes a mostly stable operating environment and excludes items such as facility sale gains, debt retirement losses, legal claim costs, and asset impairments. It also reflects risks including tariffs, Medicaid and Medicare policy changes, the expiration of enhanced ACA premium tax credits, and the continuing effects of the 2024 hurricanes.

How strong is HCA's balance sheet and what does the leverage look like?

HCA is highly leveraged. Total debt was $44.576 billion at March 31, 2025, including $3.519 billion due within one year, against $1.060 billion of cash and total assets of $59.798 billion. Stockholders' equity including noncontrolling interests was $(438) million, and the deficit attributable to HCA widened to $(3.519) billion. The company had $7.766 billion available under its credit facility. The deficit reflects years of repurchases and distributions, so investors should weigh buyback funding against debt levels and the company's ability to refinance.

What is the dividend and how does it fit into capital returns?

HCA's board declared a quarterly cash dividend of $0.72 per share, payable June 30, 2025 to holders of record on June 16, 2025. The dividend totaled $180 million in Q1 2025, a small amount compared with the $2.506 billion spent on share repurchases in the quarter. Future dividends remain at the board's discretion and are expected to be funded from cash balances and operating cash flow. Total capital returned in the quarter was therefore driven mostly by buybacks.

HCA 8-K: Earnings & Results & Regulation FD

01—Abstract

Summary

Summary of the 8-K filed April 25, 2025. Cited figures are marked; the original filing is the authoritative source.

HCA Healthcare reported first quarter 2025 results (quarter ended March 31, 2025) with revenues of $18.321 billion^a, up from $17.339 billion a year earlier, and net income attributable to HCA of $1.610 billion, or $6.45 per diluted share, versus $5.93 in the prior-year quarter.

The prior-year figure included $201 million^b in facility sale gains ($0.57 per share), so on an adjusted basis EPS grew from $5.36 to $6.45, roughly 20 percent. Adjusted EBITDA rose to $3.733 billion from $3.353 billion, with the margin expanding to 20.4 percent from 19.3 percent. Volume trends were solid: same facility admissions rose 2.6 percent, same facility equivalent admissions rose 2.8 percent, emergency room visits rose 4.0 percent, and same facility revenue per equivalent admission increased 2.9 percent.

Outpatient surgery cases declined 2.1 percent on a same facility basis, a soft spot in the quarter. Cash generation weakened in the quarter. Operating cash flow fell to $1.651 billion^c from $2.469 billion, driven largely by a $1.000 billion outflow from accounts payable and accrued expenses.

Capital expenditures were $991 million^d. HCA returned substantial capital to shareholders, repurchasing 7.762 million shares for $2.506 billion, leaving $8.259 billion under its authorization. Total debt stood at $44.576 billion against cash of $1.060 billion, and stockholders' deficit widened to $(3.519) billion attributable to HCA.

Leverage and the buyback pace relative to free cash flow are the key watch items for investors. Management reaffirmed 2025 guidance issued in January: revenues of $72.8 to $75.8 billion, Adjusted EBITDA of $14.3 to $15.1 billion, and diluted EPS of $24.05 to $25.85.

The board declared a quarterly dividend of $0.72 per share, payable June 30, 2025 to holders of record on June 16, 2025. Guidance assumes a mostly stable operating environment and flags risks including tariffs, Medicaid and Medicare policy changes, expiring enhanced ACA premium tax credits, and lingering impacts from the 2024 hurricanes.

02—Key points

Key Highlights

Q1 2025 revenue rose 5.7% to $18.321 billion, and GAAP diluted EPS of $6.45 compares with $5.93 in Q1 2024, which included a $0.57 gain on facility sales
Adjusted EBITDA increased 11.3% to $3.733 billion, and the Adjusted EBITDA margin expanded to 20.4% from 19.3%
Same facility admissions grew 2.6% and equivalent admissions grew 2.8%, while same facility revenue per equivalent admission rose 2.9%
Operating cash flow fell sharply to $1.651 billion from $2.469 billion, largely due to a $1.0 billion working capital outflow in accounts payable and accrued expenses
HCA repurchased $2.506 billion of its stock (7.762 million shares) in the quarter and retains $8.259 billion of buyback authorization
2025 guidance was reaffirmed: revenue of $72.8–$75.8 billion, Adjusted EBITDA of $14.3–$15.1 billion, and diluted EPS of $24.05–$25.85
Total debt of $44.576 billion against $1.060 billion of cash, with a stockholders' deficit attributable to HCA of $(3.519) billion, and a quarterly dividend of $0.72 per share declared

03—Questions

Frequently Asked Questions

Did HCA's earnings growth come from core operations or one-time items?
Mostly core operations. Q1 2024 included a $201 million pre-tax gain on facility sales ($154 million after tax, or $0.57 per diluted share), while Q1 2025 had only a negligible $1 million gain. Excluding these items, adjusted EPS rose from $5.36 to $6.45, about 20%, and Adjusted EBITDA grew 11.3%. Part of the EPS growth also reflects a lower share count, which fell from 268.0 million to 249.4 million diluted shares following buybacks.
Why did operating cash flow decline so much, and should investors be concerned?
Operating cash flow dropped to $1.651 billion from $2.469 billion, mainly because of a $1.000 billion decrease from accounts payable and accrued expenses and a $327 million increase in accounts receivable. Accounts receivable rose to $11.088 billion. Working capital timing can reverse in later quarters, but investors should monitor whether collections and payables normalize. Operating cash flow of $1.651 billion still exceeded capital expenditures of $991 million, and HCA's buybacks of $2.506 billion were funded in part by new debt issuance of $5.233 billion.
Is HCA's guidance changing for 2025?
No. The company reaffirmed the 2025 ranges issued in January 2025: revenue of $72.8–$75.8 billion, Adjusted EBITDA of $14.3–$15.1 billion, and diluted EPS of $24.05–$25.85 on 243 million diluted shares. Guidance assumes a mostly stable operating environment and excludes items such as facility sale gains, debt retirement losses, legal claim costs, and asset impairments. It also reflects risks including tariffs, Medicaid and Medicare policy changes, the expiration of enhanced ACA premium tax credits, and the continuing effects of the 2024 hurricanes.
How strong is HCA's balance sheet and what does the leverage look like?
HCA is highly leveraged. Total debt was $44.576 billion at March 31, 2025, including $3.519 billion due within one year, against $1.060 billion of cash and total assets of $59.798 billion. Stockholders' equity including noncontrolling interests was $(438) million, and the deficit attributable to HCA widened to $(3.519) billion. The company had $7.766 billion available under its credit facility. The deficit reflects years of repurchases and distributions, so investors should weigh buyback funding against debt levels and the company's ability to refinance.
What is the dividend and how does it fit into capital returns?
HCA's board declared a quarterly cash dividend of $0.72 per share, payable June 30, 2025 to holders of record on June 16, 2025. The dividend totaled $180 million in Q1 2025, a small amount compared with the $2.506 billion spent on share repurchases in the quarter. Future dividends remain at the board's discretion and are expected to be funded from cash balances and operating cash flow. Total capital returned in the quarter was therefore driven mostly by buybacks.

04—Continue

← View all 8-K filings